Cipla Ltd Dividend and filings and Product and market updates

$CIPLA The board recommended a final dividend of ₹13 per share for FY26. Exchange notices also show a board meeting scheduled for 23 July 2026, along with routine shareholder communication about transfer of shares to the Investor Education and Protection Fund and other compliance items. Cipla continues to highlight new launches and approvals, including respiratory and specialty products, through its media centre. Recent company releases mention U.S. FDA approval for a generic Ventolin HFA equivalent, approval for nintedanib capsules in the U.S., and a broader push in respiratory and anti-infective therapies.